Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, PET, FVT

Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference



SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference, being held on October 11, 2017 in New York City. The event will feature one-on-one meetings at which investors will have the opportunity to meet with management to discuss key therapeutic programs in development and upcoming milestones.

Kindred Biosciences, Inc. Logo

About Kindred Biosciences 

Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com 
(650) 701-7904

 

SOURCE Kindred Biosciences, Inc.


These press releases may also interest you

at 07:03
Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn's disease expected in mid-2018Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection expected in the second half of 2018Net...

at 07:03
DiaMedica Therapeutics Inc. ("DiaMedica") , a clinical stage biopharmaceutical company focused on improving lives of patients with neurological and kidney diseases associated with low...

at 07:02
FirstLight Home Care, a leading national provider of non-medical home care, has been ranked No. 37 on Franchise Business Review's 'Overall Top 50 ? The Best of the Best' list, based on franchise owner satisfaction. This...

at 07:00
Kite, a Gilead Company and Sangamo Therapeutics, Inc. today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell...

at 07:00
AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life, today announced expansion of its industry-leading container closure integrity...

at 07:00
WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on CTRE, GEO, HCP, and HR which can be accessed for free by signing up to www.wallstequities.com/registration. On Wednesday,...




News published on 5 october 2017 at 16:01 and distributed by: